What is the typical dosage and treatment protocol for Citalopram (Celexa) (Selective Serotonin Reuptake Inhibitor) for depression?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Citalopram (Celexa) Dosage and Treatment Protocol for Depression

The typical dosage range for Citalopram (Celexa) for depression is 20-40 mg once daily, with a starting dose of 20 mg and a maximum recommended dose of 40 mg due to risk of QT prolongation. 1

Initial Dosing and Titration

  • Starting dose: 20 mg once daily (morning or evening, with or without food) 1
  • Dose titration: Increase to maximum of 40 mg/day at intervals of no less than one week 1
  • Maximum dose: 40 mg/day (doses above this are not recommended due to risk of QT prolongation) 1

Special Population Considerations

Dose Adjustments Required:

  • Elderly patients (>60 years): Maximum 20 mg/day 1
  • Hepatic impairment: Maximum 20 mg/day 1
  • CYP2C19 poor metabolizers: Maximum 20 mg/day 1
  • Patients taking CYP2C19 inhibitors (e.g., cimetidine): Maximum 20 mg/day 1
  • Renal impairment:
    • Mild to moderate: No adjustment needed
    • Severe: Use with caution 1

Duration of Treatment

  • First episode of depression: Continue treatment for 4-12 months after remission 2
  • Recurrent depression: May benefit from prolonged treatment 2
    • After first episode: 50% probability of recurrence
    • After second episode: 70% probability of recurrence
    • After third episode: 90% probability of recurrence 2

Efficacy Considerations

  • Citalopram is most effective in patients with severe depression compared to those with mild to moderate depression 2
  • Doses of 40 mg/day have shown greater efficacy than lower doses in clinical trials 1, 3
  • Therapeutic plasma concentration range: 30-130 ng/mL 2

Discontinuation Protocol

  • Never discontinue abruptly - gradual tapering is essential to prevent discontinuation symptoms 1
  • Recommended approach:
    1. Decrease dose gradually
    2. If intolerable symptoms occur during tapering, resume previously prescribed dose
    3. Continue decreasing at a more gradual rate 1

Monitoring

  • Regular follow-up within 2-4 weeks of starting therapy or after dose changes 4
  • Monitor for:
    • Clinical response
    • Side effects (especially QT prolongation at higher doses)
    • Emergence of suicidal thoughts (particularly in adolescents and young adults)

Common Side Effects

  • Nausea
  • Dry mouth
  • Somnolence
  • Insomnia
  • Increased sweating 3

Important Precautions

  • QT prolongation risk: Doses above 40 mg/day are not recommended 1
  • Drug interactions: Use caution with CYP2C19 inhibitors (e.g., omeprazole) and CYP3A4 inhibitors (e.g., ketoconazole) 1
  • Pregnancy: Use caution, especially in third trimester (risk of neonatal complications) 4
  • MAOIs: Allow at least 14 days between discontinuing MAOIs and starting citalopram 1

Clinical Pearl

While citalopram is considered one of the preferred SSRIs due to its favorable side effect profile 2, the FDA has placed a firm limit on maximum dosing at 40 mg/day due to dose-dependent QT interval prolongation risk. This distinguishes it from some other SSRIs that can be safely titrated to higher doses.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Psychopharmacology for Depression and Related Conditions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.